Press Releases Search News Category Company ReleasesCompany StatementsFinancial ReleasesProduct Releases Year None20222021202020192018201720162015201420132012201120102009200820072006 Date Title PDF Version Jun 29, 2020 ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS) Jun 24, 2020 Alexion Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint Jun 17, 2020 Alexion Charitable Foundation Announces First Rare Belonging® Grants Jun 17, 2020 Alexion to Present at the 2020 Bank of America Virtual Napa Biotech Conference Jun 04, 2020 Alexion to Present at the 41st Annual Global Goldman Sachs Healthcare Conference May 14, 2020 Alexion Announces Upcoming Data Presentations at the Virtual 25th Congress of the European Hematology Association May 06, 2020 Alexion Reports First Quarter 2020 Results May 05, 2020 Alexion to Present at the Virtual Bank of America Securities 2020 Healthcare Conference May 05, 2020 Alexion to Acquire Portola May 01, 2020 Alexion Receives CHMP Positive Opinion for ULTOMIRIS® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS) Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 41 - 50 of 614